Skip to main content
JW (Cayman) Therapeutics Co. Ltd logo

JW (Cayman) Therapeutics Co. Ltd — Investor Relations & Filings

Ticker · 2126 ISIN · KYG5210T1040 LEI · 9845004E84F2D2AB6E81 HKEX Manufacturing
Open in API
Filings indexed 283 across all filing types
Latest filing 2026-05-19 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 2126

About JW (Cayman) Therapeutics Co. Ltd

http://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co. Ltd is an innovative biotechnology company focused on the research, development, manufacturing, and commercialization of cellular immunotherapy products. The company maintains an integrated, international-leading cell therapy platform supporting a comprehensive product pipeline that targets hematological malignancies, solid tumors, and autoimmune diseases. Positioned as a pioneer in the field, JW Therapeutics aims to transform cancer treatment for patients globally, with a primary focus on the China market. Its commercialized portfolio includes Relmacabtagene Autoleucel (Relma-cel, trade name: Bynoda®), a CAR-T therapy approved for use.

Recent filings

Filing Released Lang Actions
GRANT OF SHARE OPTIONS
Share Issue/Capital Change Classification · 88% confidence The document is a corporate announcement under SEHK Listing Rules disclosing the grant of share options to an executive director under the company’s Post-IPO Incentivization Scheme. It is not a financial report, management change, or insider trade report but relates to the issuance of equity rights. This falls under “Share Issue/Capital Change” (SHA) as it announces a new equity grant under the company’s share capital scheme.
2026-05-19 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return filed with the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for JW (Cayman) Therapeutics Co. Ltd for the month ended 30 April 2026. It includes detailed information on authorized and issued share capital, movements in issued shares and treasury shares, share option schemes, confirmations of compliance with listing rules, and other related disclosures. The document is a regulatory submission specifically about share capital changes and share option movements, not a financial report, earnings release, or management discussion. It is not an announcement of a report but a substantive regulatory filing with detailed data. The document fits the category of Regulatory Filings (RNS) as it is a compliance and disclosure filing to the exchange about share capital movements and confirmations under listing rules, and does not fit other more specific categories such as Share Issue/Capital Change (SHA) because it covers a broader range of regulatory confirmations and detailed disclosures beyond just share issuance announcements.
2026-05-07 English
2025 Environmental, Social and Governance Report
Environmental & Social Information Classification · 92% confidence The document is titled "Environmental, Social and Governance Report 2025" and contains detailed sections on ESG governance, strategy, climate change, social initiatives, supply chain management, etc. It is a full standalone ESG report prepared per HKEX ESG Reporting Code, not an announcement or summary. This matches the definition of an Environmental & Social Information report.
2026-04-28 English
2025 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT 2025' and contains comprehensive sections typical of a full annual report, including the Chairman's Statement, Financial Highlights, Management Discussion and Analysis, Corporate Governance Report, and full Consolidated Financial Statements (Profit or Loss, Financial Position, Cash Flows, etc.). It covers the full fiscal year ending December 31, 2025, and provides detailed financial data and operational analysis, confirming it is the primary annual report rather than an announcement or summary. FY 2025
2026-04-28 English
GRANT OF SHARE OPTIONS AND GRANT OF RESTRICTED SHARE UNITS
Capital/Financing Update Classification · 95% confidence The document is an announcement from JW (Cayman) Therapeutics Co. Ltd regarding the grant of share options and restricted share units to employees. It details the number of options and RSUs granted, exercise prices, vesting schedules, performance targets, and clawback mechanisms. The document references compliance with the Listing Rules of the Hong Kong Stock Exchange and includes no financial statements or quarterly/yearly financial results. It is a regulatory announcement about equity incentive grants rather than a financial report or management discussion. The content fits the category of a Capital/Financing Update (CAP) because it relates to changes in the company's capital structure through share option and RSU grants. The document length is over 12,000 characters, indicating it is a full announcement, not a brief notice or report publication announcement.
2026-04-20 English
Monthly Return of Equity Issuers on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 85% confidence The document is a statutory monthly return (Form FF301) filed by JW (Cayman) Therapeutics Co. Ltd. with Hong Kong Exchanges and Clearing Limited under Chapter 19B of the Listing Rules. It provides detailed movements in authorised/registered share capital, issued shares, treasury shares, share options, RSUs, and other arrangements. It is not an annual/interim report, earnings release, board/management change, or dividend notice. It is a routine regulatory submission covering capital structure movements. No specific category for a monthly share movement return exists, so the fallback “Regulatory Filings” (RNS) is the correct classification.
2026-04-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.